Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Allergy Clin Immunol. Author manuscript; available in PMC 2013 August 1.
Published in final edited form as:
PMCID: PMC3551624

Protection from asthma in a high-risk birth cohort by attenuated P2X7 function



Viral illnesses are important factors in both asthma inception and exacerbations, and allergic sensitization in early life further enhances asthma risk through unclear mechanisms. Cellular damage due to infection or allergen inhalation increases ATP in the airways with subsequent purinergic receptor activation. The purinergic receptor P2X7 may enhance airway leukocyte recruitment to the airways and P2X7 knockout mice display a reduced asthma-like phenotype.


Based upon the P2X7 knockout mouse, we hypothesized that children with low functioning P2X7 would have decreased rates of asthma.


We utilized a functional assay to determine P2X7 pore-producing capacity in whole blood samples in a birth cohort study at high risk for asthma development. The P2X7 assay was validated with known loss-of-function alleles in humans. P2X7 pore status categorization was used to assess asthma and allergy status in the cohort.


Attenuated P2X7 function was associated with lower asthma rates at ages 6 and 8 and the greatest effects were observed in boys. Children with asthma at age 11 who had low P2X7 capacity had less severe disease in the previous year. Attenuated P2X7 function was also associated with sensitization to fewer aeroallergens.


P2X7 functional capacity is associated with asthma risk or disease severity and these relationships appear to be age-related.

Keywords: asthma, allergy, children, P2X7, ATP


Sensitization to aeroallergens and the occurrence of virus-associated wheezing illnesses are early childhood events known to increase the risk of developing asthma, and the occurrence of either is thought to be due to a balance between environmental and host factors.1,2 Our group previously reported a significantly increased risk of asthma at age 6 years with acute wheezing illnesses in the first 3 years of life associated with human rhinovirus HRV),3 and aeroallergen sensitization may contribute to the risk of more severe virus-induced wheezing illnesses and asthma.46 The risk of HRV wheeze may also depend on factors related to the virus,79 and susceptible individuals may be identified by attenuated antiviral defense mechanisms leading to compromised Type I and III interferon (IFN) production.1012 Unfortunately, less is known about the control of allergic sensitization and the diverse molecular patterns and innate immune receptors comprising recognition of aeroallergens.1316 Additionally, the transition from innate to adaptive immune responses is thought to be pivotal in developing sensitization.1719 A recent example is the observation that chronic activation of dendritic cells (DCs) enhances development of polysensitization to new aeroallergens.20 Although these findings have provided new insights, determining additional characteristics of allergen-host interactions will further identify potential interventions important in asthma.

In this regard, a growing body of evidence supports the function of nucleotides and nucleotide receptors in the regulation of innate to adaptive responses.15,21,22 Injury and inflammation in the lung lead to cell damage and subsequent release of intracellular danger signals in the airways including adenosine 5’-triphosphate (ATP),2325 a natural ligand for a family of purinergic receptors.26 Granulocytic cell influx to the airways after allergen challenge is linked to levels of ATP and is blunted when ATP is hydrolyzed or purinergic receptor antagonists are administered.23,27 Specifically, an absence of P2X7 leads to a lack of pro-inflammatory cytokine interleukin (IL)-1β release28 and prevents contact dermatitis in a mouse model.29 A sensitization and exposure model of allergic asthma in P2X7 knockout mice showed decreased airway reactivity and fewer immune cells recruited to the lung after challenge.30 The immunologic amplification loop involving extracellular ATP and P2X7 has been implicated in a growing number of diseases where the resulting pathology is determined by the site at which ATP is released including at neuroreceptors, in the liver, vasculature, and the lung.2933

Since P2X7 contributes to responses from both allergens and pathogens, we sought to assess the association between P2X7 function and the development of asthma in a birth cohort at high risk for asthma and allergy.34 The gene encoding the P2X7 receptor (P2RX7) is polymorphic with non-synonymous single nucleotide polymorphisms (SNPs) resulting in functional alterations.35 These functional differences allow us to utilize a flow cytometric assay to assess whether an individual’s P2RX7 genotype confers normal or loss-of-function (LOF) potential for cell membrane pore formation.36,37 Based upon the P2RX7 knockout mouse,30 we hypothesized that low P2X7 pore function would confer protection from asthma. We demonstrate that low functioning P2X7, as measured in peripheral blood monocytes, is associated with reduced risk of childhood asthma and allergic sensitization.


Study subjects

The participants were part of the Childhood Origins of Asthma (COAST) Study, a previously described longitudinal study of a birth cohort that enrolled 289 children at high risk for development of asthma.34 All children had at least 1 parent with a history of physician-diagnosed asthma and/or respiratory allergies. All experiments were performed with approval of the Institutional Review Board and Human Subjects Committee at the University of Wisconsin-Madison; assent was obtained from the children, and informed consent was obtained from the children’s parents.

Current asthma was defined at ages 6, 8, and 11 years as described previously3 and asthma severity was assessed at age 11 years. Briefly, current asthma was diagnosed on the basis of documented presence of 1 or more of the following in the previous year: 1) physician diagnosis of asthma; 2) use of albuterol for coughing or wheezing episodes (prescribed by a physician); 3) use of a daily controller medication; 4) step-up plan including use of albuterol or short-tern use of inhaled corticosteroids during illnesses; and 5) use of prednisone for asthma exacerbation(s). Asthma severity was assessed at the 11 year visit based on National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 (EPR-3) criteria. For children using long-term controller medications, severity was classified by the level of treatment required for control of asthma, while children not on controller therapy were classified based upon symptoms.38

Wheezing respiratory tract illnesses in the first 3 years of life were previously defined by 1 or more of the following: 1) physician-diagnosed wheezing at an office visit; 2) an illness for which a child was prescribed short- or acting beta-agonists, controller medications, or both; and 3) an illness given following diagnoses: bronchiolitis, wheezing illness, reactive airway disease, asthma, and/or asthma exacerbation.3

P2X7 pore assay

Peripheral blood samples in citrate tubes were obtained from COAST children during annual study visits at ages 10 and 11 years for whole blood pore assays to assess P2X7 function.37 Briefly, 500 µL room temperature blood was twice with HEPES-buffered saline (HBS; 130 mM NaCl, 5 mM KCl, 20 mM HEPES, 0.1% bovine serum albumin, 10 mM glucose, pH 7.4) and incubated CD14 conjugated to phycoerythrin (CD14-PE, BD Biosciences, San Diego, HBS for 20 minutes. Samples were rinsed twice with potassium glutamate buffer (130 mM potassium glutamate, 5 mM KCl, 20 mM HEPES,0.1% bovine serum albumin, 10 mM glucose, pH 7.4) and incubated with 250 µM 2’(3’)-O-(f-benzoylbenzoyl) adenosine-5’-triphosphate (BzATP; Sigma, St. Louis, MO) and 1 µM YO-PRO-1 (Molecular Probes, Eugene, OR) in potassium glutamate buffer for 20 min before addition of magnesium chloride and HBS washing. Viable CD14+ cells identified by propidium iodide exclusion were examined for YO-PRO-1 median fluorescence intensity (MFI) by bead-adjusted (BD Calibrite Beads; BD Biosciences) and calibrated (RFP-30-5A; Spherotech, Lake Forest, IL) flow cytometry on a FACSCaliber (BD Biosciences). Archived DNA from COAST participants were genotyped in the lab of Dr. Carole Ober, University of Chicago. An adult population previously genotyped for P2RX7 and with P2X7 pore function measurements was also used for comparison.37 Using our previous methods,39 five functionally validated P2RX7 LOF alleles were used to genomically validate the threshold of whole blood P2X7 pore activity discriminating normal and attenuated function in both children and adults. A receiver operating characteristic (ROC) curve was used to instruct the threshold between low and normal P2X7 pore activity by maximizing sensitivity and specificity in identification of P2RX7 LOF alleles.

Allergen-specific IgE measurement

Allergen-specific IgE was measured in plasma by automated fluoroenzyme immunoassay (FEIA; Unicap 100®; Pharmacia Diagnostics AB, Uppsala, Sweden). At ages 1, 3, 6, and 9, IgE was measured for 2 species of dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus), Alternaria alternata, cat dander, and dog. At ages 6 and 9, IgE was additionally measured for ragweed, birch, timothy grass, and cockroach.40 Tests were considered positive for values ≥ 0.35 kUA/L.

Statistical analysis

The relationships between children's P2X7 pore function MFI measured on different days and obtained at different ages were examined using the Pearson correlation coefficient. Logistic regression was used to examine the relationships of asthma and viral wheezing outcomes to pore status. Multivariate logistic regression models of asthma included pore status and either gender or HRV wheeze and the interaction term as covariates. The χ2 test for association was used to compare aeroallergen sensitization rates by pore status and early life demographic and risk factors by pore status. Birth weight was compared by pore status using the Wilcoxon rank-sum test. The number of aeroallergens sensitized was compared by pore status using generalized linear mixed-effects quasi-Poisson regression models. The χ2 test for trend in proportions was used to test the association between asthma severity and pore status. P2X7 pore function measured by MFI of YO-PRO-1 uptake was normalized by square root transformation for analysis. A 2-sided P value less than 0.05 was considered statistically significant.


P2X7 Pore Assay Characteristics

At least one P2X7 pore assay was performed on 172 children in COAST during annual visits at ages 10 and 11 years. Assay results were similar to those previously performed on adults with an approximately square root normalized distribution (Figure 1A). To validate the reproducibility of our standard methods, a subset of 48 samples had pore assays performed on more than one day post-phlebotomy with an average daily coefficient of variation (CV) of 7% between the first and second day (Pearson r = 0.97, P < 0.001; Figure 1B). Additionally, a subset of 71 children had pore assays performed at both the 10- and 11-year study visits and the year-to-year reproducibility of the assay was also highly correlated (Pearson r = 0.91; P < 0.001; Figure 1C). Overall these results confirm the high reproducibility of our pore assay and independence from potential technical confounding factors.

Figure 1
P2X7 pore assay characteristics

Because the COAST P2X7 pore assays were consistent with previous adult assays, we combined both for ROC analysis using 5 validated P2RX7 LOF alleles to determine a threshold between individuals with low and normal functioning P2X7 (Figure 1D). From this analysis, a threshold of 382 MFI was identified and used to categorize all individuals with P2X7 pore assays with either low or normal P2X7 pore status, indicated by the shading in Figure 1A. The resulting performance properties of the assay in identifying LOF alleles for P2RX7 are shown in Figure 1D (P < 0.001, area under the curve (AUC) = 0.90). Low P2X7 pore capacity was observed in 28% of COAST participants, similar to rates in other populations.

P2X7 pore status is independent of many demographic factors

To determine whether P2X7 status was biased by risk factors at birth or in the first year of life, we examined the distribution of pore status across a number of risk factors for asthma. P2X7 pore status was independent of birth and early life characteristics (Table I).

Table I
P2X7 function is independent of asthma risk factors

P2X7 function, asthma inception, and disease severity

To determine the association between P2X7 function and childhood asthma, we stratified the COAST cohort by P2X7 pore status and determined the rates of asthma at ages 6, 8, and 11 years. Low P2X7 pore status was associated with a decreased rate of asthma (Figure 2A) at ages 6 (Odds Ratio (OR) 0.34, 95% Confidence Interval (CI) 0.15–0.79, P = 0.01) and 8 (OR 0.42, 95% CI 0.20–0.88, P = 0.02) years, but a significant association was not observed at age 11 (OR 0.62, 95% CI 0.29–1.31, P = 0.21) years. To investigate whether there were any phenotypic effects in the children with asthma at age 11 years, we also stratified the severity of asthma by P2X7 function. Low P2X7 pore children with asthma at age 11 years had evidence of less severe asthma compared to normal P2X7 pore children with asthma (P = 0.03; Figure 2B). However, when examined at age 6 years, P2X7 pore function was not associated with asthma severity (P = 0.29). Children with low pore function and asthma at age 11 years were also less likely to have used a step-up short-term plan, used for temporary loss of acceptable control with respiratory tract illnesses,41 in the previous year (OR 0.26, 95% CI 0.07–1.00, P = 0.04).

Figure 2
Low P2X7 pore function is protective from asthma development

P2X7 function is associated with early life wheezing with HRV

Due to P2X7’s role in infections and airway reactivity30,42 and our previous observation that wheezing illnesses associated with HRV in the first 3 years of life correspond to an increased rate of asthma,3 we assessed the rates of wheezing in early life with or without virus detected based upon P2X7 functional groups. Low P2X7 pore status was not associated with preschool wheezing in general, but was associated with decreased wheezing associated with HRV infections in the first 3 years of life (Table II).

Table II
P2X7 and early life wheezing

Decreased asthma risk associated with attenuated P2X7 function is varied by a history of HRV wheezing and gender

To test whether reduced asthma risk in low P2X7 individuals was only due to the association with decreased early life HRV wheezing, we modeled the interaction of P2X7 status and HRV wheezing on asthma diagnosis by logistic regression. The greatest risk for asthma was present in children who had the combination of normal P2X7 function and a history of HRV wheezing in the first 3 years of life (Figure 3A), and this interaction was significant at ages 6 (P = 0.03) and 8 (P = 0.01) years.

Figure 3
Interactions of P2X7 with HRV wheezing and gender

Due to different rates of asthma in boys and girls at different ages,43 we also examined whether there was an interaction between gender and P2X7 status with regard to asthma risk by logistic regression. The protective effect of low P2X7 pore status was more pronounced in boys than girls (Figure 3B) and a significant interaction between gender and P2X7 pore status was observed at ages 8 (P = 0.02) and 11 (P = 0.03) years. When only including boys in factoring asthma risk by P2X7 pore status, protection from asthma in boys was significantly associated with low pore status at ages 6 (OR 0.20, 95% CI 0.06–0.64, P = 0.004), 8 (OR 0.19, 95% CI 0.06–0.54, P = 0.001), and 11 (OR 0.30, 95% CI 0.10–0.87, P = 0.02) years.

Allergic polysensitization and P2X7 status

Effects of P2X7 function on allergic sensitization rates have not previously been tested. In COAST, children with low P2X7 function were less likely to be sensitized to common aeroallergens at age 3 years (P = 0.04), with a similar trend at age 9 years (P = 0.07; Figure 4A). Because increased activation of DCs is reported to increase rates of polysensitization,20 we also examined the rates of sensitization to aeroallergens as the average number of positive sensitizations per child. When 5 common aeroallergens were modeled by mixed effects quasi-Poisson regression, low P2X7 children were sensitized to fewer aeroallergens across ages 1, 3, 6, and 9 years (Figure 4B; mean fold change = 0.45, 95% CI 0.22–0.91, P = 0.03). At individual ages, low P2X7 children were sensitized to significantly fewer allergens at age 6 years (P = 0.02) and low P2X7 children trended to be sensitized to fewer allergens at ages 3 (P = 0.09) and 9 (P = 0.07) years. When including additional aeroallergens measured only at ages 6 and 9 years, a similar trend was observed, but the model no longer remained significant across both years (P = 0.14).

Figure 4
Aeroallergen sensitization status


This study adds to a growing body of research revolving around the role of nucleotides in airway disease. Similar to previous work in adults, we demonstrate good performance of a whole blood P2X7 functional assay as a method to detect P2RX7 LOF alleles (Figure 1). By utilizing this robust assay, we have demonstrated that a lack of P2X7 pore activity in high-risk children is associated with a reduced risk of asthma (Figure 2), as well as sensitization to fewer aeroallergens (Figure 4). However, the mechanisms underlying these observations are not clear. Discerning the role of P2X7 activation by extracellular ATP in concert with secondary signals including allergen exposure and/or viral infections may help determine how P2X7 activity could modulate risk of chronic conditions such as asthma.

Previous studies indicate the amount of extracellular ATP may be related to airway disease severity.25 Rather than directly measuring ATP in the airway after injurious events, our study has the strength to study the potential for differential host responses to natural in vivo extracellular ATP fluctuations. Our results (Figure 1D) recapitulate that considerably more contributes to P2X7 pore function than validated P2RX7 LOF alleles and illustrates the power of our functional approach to evaluate potential gene-by-environment interactions. The COAST population has already demonstrated gene-by-environment interactions including between IFNG and sex44 which may be important to in vivo P2X7 function since IFN-γ reportedly regulates P2X7.45 Although our current results are from pre-pubertal children, they display a varied risk of asthma by P2X7 status based on gender (Figure 3B). Whether the dynamics of this relationship change during and after puberty will be of great interest.

Our current results are in general agreement with findings from P2X7 knockout mice wherein low P2X7 function is protective from asthma-like symptoms.30 These P2X7 knockout mice demonstrate decreased cell influx into the lung after allergen or smoke challenge,30,46 and we have previously shown a decreased neutrophil infiltration in the nose during an acute cold in adults with low P2X7 function.47 Although our current study may have been strengthened if P2X7 pore assays could have been performed in early life before the earliest asthma evaluations, the high reproducibility and genetic basis of our results (Figure 1) indicates assays should be similar at any age and mitigate these potential concerns.

While low P2X7 pore status protection from asthma in the current COAST cohort is consistent over multiple ages, these results seem counter to the inverse relationship between P2X7 function and exacerbation risks in adults with a natural cold.47 Differences in study populations and in the pathogenesis of asthma inception compared to exacerbations may help reconcile these findings. There are significant differences in study populations: the COAST population is comprised of high risk children followed prospectively from birth, while the previous study enrolled symptomatic asthmatic adults during the peak cold season. In the children asthma was more common in boys, while in adults asthma was predominantly observed in women. It is possible the overall lack of association at age 11 years between asthma and P2X7 status may continue to change throughout puberty into adulthood and reflect the exacerbation risks observed in adults. Specifically, it is intriguing to note that a small percentage of children had both low P2X7 status and a history of HRV wheezing and that this group demonstrated the largest shift in rates of current asthma at different ages. Whether modification of P2X7 function from nucleotide activation is sufficient to alter asthma outcomes in humans has yet to be measured.

How does P2X7 influence asthma risk? While P2X7 is present in airway epithelial cells, the receptor is more highly expressed and active in immune cells, including DCs.4850 Both nucleotides and nucleotide receptors, including P2X7, impact DC function27,30,4952 and loss of P2X7 function – specifically from LOF alleles detected by our pore assay – leads to a decrease in DC pore activity as well as other P2X7-dependent functional responses.50,51 T cell maturation, including Treg and TH17 phenotypes, is modified by nucleotide activity upon T cells and DCs, either directly or by engaging pathways associated with P2X7 including the NLRP3 inflammasome or pannexin-1 and suggest that functional P2X7 activation may lead to a decrease in Treg populations.5357 A DC-focused role of P2X7 is supportive of an amplified response to infections or allergens when co-mingled with danger signals acting as adjuvants. Our study demonstrates a potential role for monitoring host responsiveness to immunomodulatory danger signals.

P2X7 sits at a balance point in the immune system in response to allergic and infectious events. It is not clear whether a single episode of P2X7 activation is sufficient to increase the risk of asthma or whether frequent stimulation is required. Moreover, P2X7 function may not always b e beneficial or harmful in the immune response; the role of P2X7 may be different when comparing disease inception to active, chronic conditions with superimposed acute events such as exacerbations. As examples, influenza virus activation of the inflammasome has been linked to P2X7 function58 while another report suggests P2X7 may be necessary for some viruses to achieve cell entry.59 Whether P2X7 plays an active role in HRV infection or is secondary and solely responsive to cell injury could indicate when and where alterations of P2X7 function are relevant. To study these relationships, the P2X7 pore assay system described in this report is a useful tool to identify individuals at altered risk for disease and should be considered when further studying the role of danger signaling in disease pathogenesis.

Key Message

  • P2X7 functional capacity is easily assessed in children
  • Low P2X7 function may decrease susceptibility to diseases including asthma


We gratefully thank all study participants and past and present coordinators for COAST. We also thank Dr. Carole Ober, PhD, University of Chicago, for assistance with sample genotyping.

Funding: Supported by NIH grants: P01 HL070831, K23 HL081492, and the project described was supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR), grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.


area under the curve
2’ (3’)-O-(f-Benzoylbenzoyl)adenosine-5’-triphosphate
confidence interval
Childhood Origins of ASThma
coefficient of variation
dendritic cell
deoxyribonucleic acid
expert panel report 3
fluoroenzyme immunoassay
HEPES-buffered saline
human rhinovirus
median fluorescence intensity
national asthma education and prevention program
odds ratio
receiver operating characteristic
respiratory syncytial virus
single nucleotide polymorphism


1. Busse WW, Lemanske RF, Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010 Sep 4;376(9743):826–834. [PMC free article] [PubMed]
2. Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. Expert Rev Respir Med. 2010 Feb;4(1):71–83. [PMC free article] [PubMed]
3. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008 Oct 1;178(7):667–672. [PMC free article] [PubMed]
4. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, et al. Evidence for a Causal Relationship Between Allergic Sensitization and Rhinovirus Wheezing in Early Life. Am J Respir Crit Care Med. 2011 Sep 29; [PMC free article] [PubMed]
5. Celedon JC, Milton DK, Ramsey CD, Litonjua AA, Ryan L, Platts-Mills TA, et al. Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood. J Allergy Clin Immunol. 2007 Jul;120(1):144–149. [PMC free article] [PubMed]
6. Sly PD, Boner AL, Bjorksten B, Bush A, Custovic A, Eigenmann PA, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet. 2008 Sep 20;372(9643):1100–1106. [PMC free article] [PubMed]
7. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J. 2011 May;37(5):1037–1042. [PMC free article] [PubMed]
8. Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB, et al. Human Rhinovirus Species Associated With Hospitalizations for Acute Respiratory Illness in Young US Children. J Infect Dis. 2011 Dec;204(11):1702–1710. [PubMed]
9. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 2009 Apr 3;324(5923):55–59. [PMC free article] [PubMed]
10. Forbes RL, Gibson PG, Murphy VE, Wark PA. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma. Thorax. 2011 Nov 5; [PubMed]
11. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL. A defective type 1 response to rhinovirus in atopic asthma. Thorax. 2002 Apr;57(4):328–332. [PMC free article] [PubMed]
12. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005 Mar 21;201(6):937–947. [PMC free article] [PubMed]
13. Minnicozzi M, Sawyer RT, Fenton MJ. Innate immunity in allergic disease. Immunol Rev. 2011 Jul;242(1):106–127. [PubMed]
14. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. 2009 Apr;15(4):410–416. [PMC free article] [PubMed]
15. Willart MA, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy. 2009 Jan;39(1):12–19. [PubMed]
16. Georas SN, Rezaee F, Lerner L, Beck L. Dangerous allergens: why some allergens are bad actors. Curr Allergy Asthma Rep. 2010 Mar;10(2):92–98. [PMC free article] [PubMed]
17. Holt PG, Sly PD. Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest. 2011 May;139(5):1165–1171. [PubMed]
18. Sly PD, Holt PG. Role of innate immunity in the development of allergy and asthma. Curr Opin Allergy Clin Immunol. 2011 Apr;11(2):127–131. [PubMed]
19. Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol. 2007 Dec;120(6):1279–1284. [PMC free article] [PubMed]
20. van Rijt LS, Vos N, Willart M, Muskens F, Tak PP, van der Horst C, et al. Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice. Am J Respir Crit Care Med. 2011 Aug 1;184(3):303–311. [PubMed]
21. Rathinam VA, Fitzgerald KA. Inflammasomes and anti-viral immunity. J Clin Immunol. 2010 Sep;30(5):632–637. [PubMed]
22. Willart MA, Hammad H. Alarming dendritic cells for allergic sensitization. Allergol Int. 2010 Jun;59(2):95–103. [PubMed]
23. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007 Aug;13(8):913–919. [PubMed]
24. Yin J, Xu K, Zhang J, Kumar A, Yu FS. Wound-induced ATP release and EGF receptor activation in epithelial cells. J Cell Sci. 2007 Mar 1;120(Pt 5):815–825. [PMC free article] [PubMed]
25. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 May 1;181(9):928–934. [PubMed]
26. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006 Aug 3;442(7102):527–532. [PubMed]
27. Muller T, Robaye B, Vieira RP, Ferrari D, Grimm M, Jakob T, et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy. 2010 Dec;65(12):1545–1553. [PubMed]
28. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol. 2002 Jun 15;168(12):6436–6445. [PubMed]
29. Weber FC, Esser PR, Muller T, Ganesan J, Pellegatti P, Simon MM, et al. Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med. 2010 Nov 22;207(12):2609–2619. [PMC free article] [PubMed]
30. Muller T, Vieira RP, Grimm M, Durk T, Cicko S, Zeiser R, et al. A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol. 2011 Apr;44(4):456–464. [PubMed]
31. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005 Apr;114(3):386–396. [PubMed]
32. Schneider EM, Flacke S, Liu F, Lorenz MR, Schilling P, Nass ME, et al. Autophagy and ATP-induced anti-apoptosis in antigen presenting cells (APC) follows the cytokine storm in patients after major trauma. J Cell Commun Signal. 2011 Jun;5(2):145–156. [PMC free article] [PubMed]
33. Wilhelm K, Ganesan J, Muller T, Durr C, Grimm M, Beilhack A, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010 Dec;16(12):1434–1438. [PubMed]
34. Lemanske RF., Jr The childhood origins of asthma (COAST) study. Pediatr Allergy Immunol. 2002;13(Suppl 15):38–43. [PubMed]
35. Fuller SJ, Stokes L, Skarratt KK, Gu BJ, Wiley JS. Genetics of the P2X7 receptor and human disease. Purinergic Signal. 2009 Jun;5(2):257–262. [PMC free article] [PubMed]
36. Denlinger LC, Angelini G, Schell K, Green DN, Guadarrama AG, Prabhu U, et al. Detection of human P2X7 nucleotide receptor polymorphisms by a novel monocyte pore assay predictive of alterations in lipopolysaccharide-induced cytokine production. J Immunol. 2005 Apr 1;174(7):4424–4431. [PubMed]
37. Korpi-Steiner NL, Sheerar D, Puffer EB, Urben C, Boyd J, Guadarrama A, et al. Standardized method to minimize variability in a functional P2X(7) flow cytometric assay for a multi-center clinical trial. Cytometry B Clin Cytom. 2008 Sep;74(5):319–329. [PMC free article] [PubMed]
38. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94–S138. [PubMed]
39. Denlinger LC, Coursin DB, Schell K, Angelini G, Green DN, Guadarrama AG, et al. Human P2X7 pore function predicts allele linkage disequilibrium. Clin Chem. 2006 Jun;52(6):995–1004. [PubMed]
40. Possin ME, Morgan S, DaSilva DF, Tisler C, Pappas TE, Roberg KA, et al. The relationships among immunoglobulin levels, allergic sensitization, and viral respiratory illnesses in early childhood. Pediatr Allergy Immunol. 2010 Sep;21(6):990–996. [PMC free article] [PubMed]
41. Thomas A, Lemanske RF, Jr, Jackson DJ. Approaches to stepping up and stepping down care in asthmatic patients. J Allergy Clin Immunol. 2011 Nov;128(5):915–924. quiz 25–6. [PMC free article] [PubMed]
42. Saunders BM, Fernando SL, Sluyter R, Britton WJ, Wiley JS. A loss-of-function polymorphism in the human P2X7 receptor abolishes ATP-mediated killing of mycobacteria. J Immunol. 2003 Nov 15;171(10):5442–5446. [PubMed]
43. Vink NM, Postma DS, Schouten JP, Rosmalen JG, Boezen HM. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. J Allergy Clin Immunol. 2010 Sep;126(3):498–504. e1–6. [PubMed]
44. Loisel DA, Tan Z, Tisler CJ, Evans MD, Gangnon RE, Jackson DJ, et al. IFNG genotype and sex interact to influence the risk of childhood asthma. J Allergy Clin Immunol. 2011 Sep;128(3):524–531. [PMC free article] [PubMed]
45. Humphreys BD, Dubyak GR. Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol. 1998 Aug;64(2):265–273. [PubMed]
46. Lucattelli M, Cicko S, Muller T, Lommatzsch M, De Cunto G, Cardini S, et al. P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol. 2011 Mar;44(3):423–429. [PubMed]
47. Denlinger LC, Shi L, Guadarrama A, Schell K, Green D, Morrin A, et al. Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control. Am J Respir Crit Care Med. 2009 Feb 15;179(4):265–270. [PMC free article] [PubMed]
48. Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS. Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors. Am J Physiol Cell Physiol. 2000 Oct;279(4):C1189–C1197. [PubMed]
49. Coutinho-Silva R, Persechini PM, Bisaggio RD, Perfettini JL, Neto AC, Kanellopoulos JM, et al. P2Z/P2X7 receptor-dependent apoptosis of dendritic cells. Am J Physiol. 1999 May;276(5 Pt 1):C1139–C1147. [PubMed]
50. Georgiou JG, Skarratt KK, Fuller SJ, Martin CJ, Christopherson RI, Wiley JS, et al. Human epidermal and monocyte-derived langerhans cells express functional P2X receptors. J Invest Dermatol. 2005 Sep;125(3):482–490. [PubMed]
51. Sluyter R, Wiley JS. Extracellular adenosine 5'-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. Int Immunol. 2002 Dec;14(12):1415–1421. [PubMed]
52. Baroni M, Pizzirani C, Pinotti M, Ferrari D, Adinolfi E, Calzavarini S, et al. Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. FASEB J. 2007 Jun;21(8):1926–1933. [PubMed]
53. Kim JM. Molecular mechanisms of regulatory T cell development and suppressive function. Prog Mol Biol Transl Sci. 2010;92:279–314. [PubMed]
54. Taylor SR, Alexander DR, Cooper JC, Higgins CF, Elliott JI. Regulatory T cells are resistant to apoptosis via TCR but not P2X7. J Immunol. 2007 Mar 15;178(6):3474–3482. [PubMed]
55. Cappelli C, Lopez X, Labra Y, Montoya M, Fernandez R, Imarai M, et al. Polymyxin B increases the depletion of T regulatory cell induced by purinergic agonist. Immunobiology. 2011 Oct 23; [PubMed]
56. Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity. 2009 Jun 19;30(6):860–874. [PMC free article] [PubMed]
57. Woehrle T, Yip L, Elkhal A, Sumi Y, Chen Y, Yao Y, et al. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood. 2010 Nov 4;116(18):3475–3484. [PubMed]
58. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010 May;11(5):404–410. [PMC free article] [PubMed]
59. Taylor JM, Han Z. Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLoS One. 2010;5(12):e15784. [PMC free article] [PubMed]